Synkromax Biotech Profile
Key Indicators
- Authorised Capital ₹ 6.50 Cr
- Paid Up Capital ₹ 6.25 Cr
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 46.88 Cr
- Satisfied Charges ₹ 19.73 Cr
- Revenue Growth 3.93%
- Profit Growth 1337.14%
- Ebitda 36.59%
- Net Worth 7.78%
- Total Assets 3.18%
About Synkromax Biotech
Synkromax Biotech Private Limited (SBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 11 August 2009 and has a history of 15 years and six months. Its registered office is in Tiruvallur, Tamil Nadu, India.
The Corporate was formerly known as Shri Meera Biotech Private Limited. The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.50 Cr and a paid-up capital of Rs 6.25 Cr.
The company currently has active open charges totaling ₹46.88 Cr. The company has closed loans amounting to ₹19.73 Cr, as per Ministry of Corporate Affairs (MCA) records.
Subramanian Veluchamy and Usha Subramanian serve as directors at the Company.
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999TN2009PTC072537
- Company No.
072537
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Aug 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
What products or services does Synkromax Biotech Private Limited offer?
Synkromax Biotech Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, API (Active Pharmaceutical Ingredients), Agricultural Equipment, Agricultural Machinery, Snack Foods, Packed Food, Leather Handbag, Fashion Leather Handbag, Pharmaceutical Medicine, Insecticides.
Who are the key members and board of directors at Synkromax Biotech?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Subramanian Veluchamy ![]() | Managing Director | 09-May-2011 | Current |
Board Members (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Usha Subramanian ![]() | Director | 20-Jul-2020 | Current |
Financial Performance of Synkromax Biotech.
Synkromax Biotech Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 3.93% increase. The company also saw a substantial improvement in profitability, with a 1337.14% increase in profit. The company's net worth moved up by a moderate rise of 7.78%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Synkromax Biotech?
In 2022, Synkromax Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹46.88 Cr
₹19.73 Cr
Charges Breakdown by Lending Institutions
- Indian Overseas Bank : 46.85 Cr
- Others : 0.03 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
15 Nov 2024 | Indian Overseas Bank | ₹46.85 Cr | Open |
23 Jan 2024 | Others | ₹0.30 M | Open |
12 Jan 2023 | Bank Of India | ₹1.18 Cr | Satisfied |
06 Aug 2021 | Sidbi | ₹1.44 Cr | Satisfied |
30 Mar 2021 | Bank Of India | ₹1.41 Cr | Satisfied |
How Many Employees Work at Synkromax Biotech?
Synkromax Biotech has a workforce of 44 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Synkromax Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Synkromax Biotech's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.